<?xml version="1.0" encoding="UTF-8"?>
<p>The result of preclinical studies on rhubarb show the pharmacological activity of this plant to be highly attributed to its anthraquinones through several therapeutic targets in organs damaged in SARS-CoV-2 infection. Especially, a clinical study of the protective effects of this plant in patients with ARDS represents the significant efficacy and acceptable safety of its use in treating a condition remarkably similar to COVID-19. Thus, rhubarb could be one of the possible choices that are clinically assessed in treating this disease.</p>
